Novartis presented Phase 2 results testing Rhapsido—an approved drug for chronic hives—in food allergy, reporting that all three doses in the trial produced higher response measures versus control, the company said. Novartis framed the data as preliminary evidence to support expanding Rhapsido’s label into allergic disease indications. The company highlighted dose‑dependent signals and safety observations at the readout; detailed efficacy metrics, responder definitions, and follow‑up plans were disclosed by Novartis. The data offer a potential near‑term pathway for an existing immune‑modulatory molecule to enter a larger allergic disease market. Investors and competitors will watch for confirmatory studies and regulatory strategy as Novartis assesses whether to pursue broader approvals beyond dermatologic indications.